Phytotoxicity and metabolism of ethofumesate in transgenic rice plants expressing the human CYP2B6 gene

被引:14
|
作者
Kawahigashi, H
Hirose, S
Hayashi, E
Ohkawa, H
Ohkawa, Y
机构
[1] Natl Inst Agrobiol Sci, Plant Biotechnol Dept, Tsukuba, Ibaraki 3058602, Japan
[2] Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan
关键词
cytochrome P450; benzofuranyl alkanesulfonate; benfuresate; herbicide tolerance; germination; transgenic rice; phytoremediation;
D O I
10.1016/S0048-3575(02)00153-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transgenic rice plants expressing human CYP1A1, CYP2B6, or CYP2C19 show strong cross-tolerance to various herbicides. However, these plants showed susceptibility to the herbicides ethofumesate and benfuresate. Both herbicides inhibited germination of transgenic rice plants at a concentration of 2.0 muM in the culture medium, whereas control Nipponbare plants showed normal growth in their presence. The CYP2B6 rice plants metabolized ethofumesate to produce the de-ethylated metabolite DHDBM (2,3-dihydro-2-hydroxy-3,3-dimethyl-5-benzofuranyI methanesulfonate), which was accumulated to levels up to 60 times higher than in control plants. Germination of both control and CYP2B6 rice plants was inhibited completely with 0.75 muM DHDBM in the culture medium. The phytotoxicity of DHDBM to rice plants was at least four times greater than that of ethofumesate. Because both ethofumesate and benfuresate are metabolized to give DHDBM or analogous metabolites, we consider that DHDBM was the major phytotoxic metabolite in these rice plants. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [21] Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6
    Lu, H.
    Wang, J. J.
    Chan, K. K.
    Philip, P. A.
    XENOBIOTICA, 2006, 36 (05) : 367 - 385
  • [22] Examination of purported probes of human CYP2B6
    Ekins, S
    VandenBranden, M
    Ring, BJ
    Wrighton, SA
    PHARMACOGENETICS, 1997, 7 (03): : 165 - 179
  • [23] CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!
    Cook-Sather, Scott D.
    Adamson, Peter C.
    Li, Jin
    Hakonarson, Hakon
    ANESTHESIOLOGY, 2016, 125 (06) : 1085 - 1087
  • [24] Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study
    Dobrinas, Maria
    Crettol, Severine
    Oneda, Beatrice
    Lahyani, Rachel
    Rotger, Margalida
    Choong, Eva
    Lubomirov, Rubin
    Csajka, Chantal
    Eap, Chin B.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (02): : 84 - 93
  • [25] Detection of single nucleotide polymorphisms in CYP2B6 gene
    Zanger, UM
    Fischer, J
    Klein, K
    Lang, T
    CYTOCHROME P450, PT C, 2002, 357 : 45 - 53
  • [26] Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism
    Crane, Alice L.
    Klein, Kathrin
    Zanger, Ulrich M.
    Olson, James R.
    TOXICOLOGY, 2012, 293 (1-3) : 115 - 122
  • [27] Stereoselective metabolism of methadone (M) by CYP2B6 and CYP2C19.
    Gerber, JG
    Rhodes, RJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P11 - P11
  • [28] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [29] INFLUENCE OF CYP2B6*6 GENOTYPE ON BUPROPION ENANTIOMERS METABOLISM AND CLEARANCE
    Kharasch, E. D.
    Crafford, A.
    Parchomski, J.
    Blood, J.
    Regina, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S54 - S54
  • [30] Enzyme kinetics of valproic acid metabolism by human cDNA CYP2A6, CYP2B6, and CYP2C9*1
    Ho, PC
    Chang, TKH
    Abbott, FS
    DRUG METABOLISM REVIEWS, 2002, 34 : 112 - 112